{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T16:21:33Z","timestamp":1778862093253,"version":"3.51.4"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009432","name":"Government Council on Grants, Russian Federation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009432","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.clim.2022.109039","type":"journal-article","created":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T03:15:39Z","timestamp":1652411739000},"page":"109039","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Intravenouse immunoglobuline in dysautonomia"],"prefix":"10.1016","volume":"240","author":[{"given":"N.","family":"Gavrilova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Kamaeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ignatova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Ryabkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Lukashenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Soprun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.P.","family":"Churilov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Shoenfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2022.109039_bb0005","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1177\/0961203317696589","article-title":"Intravenous immunoglobulin: A biological corticosteroid-sparing agent in some autoimmune conditions","volume":"26","author":"Watad","year":"2017","journal-title":"Lupus."},{"key":"10.1016\/j.clim.2022.109039_bb0010","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/NAN.0000000000000248","article-title":"The role of immunoglobulin in the treatment of immune-mediated peripheral neuropathies","volume":"40","author":"Tobon","year":"2017","journal-title":"J. Infus. Nurs."},{"key":"10.1016\/j.clim.2022.109039_bb0015","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/trf.14427","article-title":"Clinical indications for intravenous immunoglobulin utilization in a tertiary medical center: a 9-year retrospective study","volume":"58","author":"Shemer","year":"2018","journal-title":"Transfusion."},{"key":"10.1016\/j.clim.2022.109039_bb0020","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/978-1-62703-586-6_18","article-title":"Idiotype-specific intravenous immunoglobulin (IVIG) for therapy of autoimmune diseases","volume":"1060","author":"Blank","year":"2014","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.clim.2022.109039_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13063-016-1450-x","article-title":"Intravenous immunoglobulin therapy for small fiber neuropathy: study protocol for a randomized controlled trial","volume":"17","author":"de Greef","year":"2016","journal-title":"Trials."},{"key":"10.1016\/j.clim.2022.109039_bb0030","first-page":"754","article-title":"The efficacy of intravenous immunoglobulin in Guillain-Barr\u00e9 syndrome: the experience of a tertiary medical center","volume":"20","author":"Shalem","year":"2018","journal-title":"Isr. Med. Assoc. J."},{"key":"10.1016\/j.clim.2022.109039_bb0035","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/intimm\/dxf099","article-title":"Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus","volume":"14","author":"Shoenfeld","year":"2002","journal-title":"Int. Immunol."},{"key":"10.1016\/j.clim.2022.109039_bb0040","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s10072-003-0081-7","article-title":"Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases","volume":"24","author":"Bayry","year":"2003","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.clim.2022.109039_bb0045","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/ane.12444","article-title":"Intravenous immunoglobulin in the treatment of neurologic disorders","volume":"133","author":"\u017divkovi\u0107","year":"2016","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.clim.2022.109039_bb0050","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/MJT.0000000000000778","article-title":"Intravenous immunoglobulin therapy in refractory autoimmune dysautonomias: a retrospective analysis of 38 patients","volume":"26","author":"Schofield","year":"2019","journal-title":"Am. J. Ther."},{"key":"10.1016\/j.clim.2022.109039_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0887-7963(05)80026-4","article-title":"IgA anaphylactic transfusion reactions","volume":"9","author":"Sandler","year":"1995","journal-title":"Transfus. Med. Rev."},{"key":"10.1016\/j.clim.2022.109039_bb0060","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.autrev.2006.08.011","article-title":"Safety of intravenous immunoglobulin (IVIG) therapy","volume":"6","author":"Katz","year":"2007","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.clim.2022.109039_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2018.01299","article-title":"Adverse effects of immunoglobulin therapy","volume":"9","author":"Guo","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2022.109039_bb0070","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1212\/WNL.61.6.736","article-title":"Practice parameter: immunotherapy for Guillain-Barr\u00e9 syndrome - report of the quality standards Subcommittee of the American Academy of neurology","volume":"61","author":"Hughes","year":"2003","journal-title":"Neurology."},{"key":"10.1016\/j.clim.2022.109039_bb0075","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0140-6736(96)09095-2","article-title":"Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome","volume":"349","author":"Hughes","year":"1997","journal-title":"Lancet."},{"key":"10.1016\/j.clim.2022.109039_bb0080","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000050777","article-title":"A preliminary, randomized, multicenter study comparing intravenous immunoglobulin, plasma exchange, and immune adsorption in Guillain-Barr\u00e9 syndrome","volume":"46","author":"Diener","year":"2001","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.clim.2022.109039_bb0085","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1080\/14712598.2018.1468885","article-title":"The immunotherapy of Guillain-Barr\u00e9 syndrome","volume":"18","author":"Restrepo-Jim\u00e9nez","year":"2018","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.clim.2022.109039_bb0090","doi-asserted-by":"crossref","DOI":"10.1007\/s100720200012","article-title":"High-dose intravenous immunoglobulin therapy in dysimmune neuropathies","volume":"23","author":"Nobile-Orazio","year":"2002","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.clim.2022.109039_bb0095","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1212\/WNL.56.4.445","article-title":"Randomized controlled trial of mg in untreated chronic inflammatory demyelinating polyradiculoneuropathy","volume":"56","author":"Mendell","year":"2001","journal-title":"Neurology."},{"key":"10.1016\/j.clim.2022.109039_bb0100","first-page":"293","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy: revisiting the role of intravenous immmunoglobulins","volume":"15","author":"Chapman","year":"2013","journal-title":"Isr. Med. Assoc. J."},{"key":"10.1016\/j.clim.2022.109039_bb0105","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/ana.1088","article-title":"Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"50","author":"Hughes","year":"2001","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.clim.2022.109039_bb0110","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","article-title":"Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial","volume":"7","author":"Hughes","year":"2008","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.clim.2022.109039_bb0115","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1542\/peds.2012-2597","article-title":"Evidence of small-fiber polyneuropathy in unexplained, juvenile-onset, widespread pain syndromes","volume":"131","author":"Oaklander","year":"2013","journal-title":"Pediatrics."},{"key":"10.1016\/j.clim.2022.109039_bb0120","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/nmo.12391","article-title":"Immunotherapy trial as diagnostic test in evaluating patients with presumed autoimmune gastrointestinal dysmotility","volume":"26","author":"Flanagan","year":"2015","journal-title":"Neurogastroenterol. Motil."},{"key":"10.1016\/j.clim.2022.109039_bb0125","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1001\/archneurol.2007.60","article-title":"Combined immunomodulatory therapy in autoimmune autonomic ganglionopathy","volume":"65","author":"Gibbons","year":"2008","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.clim.2022.109039_bb0130","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0140-6736(96)91559-7","article-title":"Idiopathic dysautonomia treated with intravenous gammaglobulin","volume":"347","author":"Heafield","year":"1996","journal-title":"Lancet."},{"key":"10.1016\/j.clim.2022.109039_bb0135","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1136\/jnnp.62.5.529","article-title":"Treatment of acute pandysautonomia with intravenous immunoglobulin","volume":"62","author":"Mericle","year":"1997","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.clim.2022.109039_bb0140","doi-asserted-by":"crossref","first-page":"333","DOI":"10.4065\/72.4.333","article-title":"Unusual recovery from acute panautonomic neuropathy after immunoglobulin therapy","volume":"72","author":"Smit","year":"1997","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.clim.2022.109039_bb0145","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1212\/WNL.51.6.1764","article-title":"Postinfectious pandysautonomia with complete recovery after intravenous immunoglobulin therapy","volume":"51","author":"Venkataraman","year":"1998","journal-title":"Neurology."},{"key":"10.1016\/j.clim.2022.109039_bb0150","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1212\/WNL.54.3.768","article-title":"The risk of abducens palsy after diagnostic lumbar puncture","volume":"54","author":"Th\u00f6mke","year":"2000","journal-title":"Neurology."},{"key":"10.1016\/j.clim.2022.109039_bb0155","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.braindev.2004.02.012","article-title":"Acute dysautonomia: complete recovery after two courses of IVIg","volume":"26","author":"Ishitobi","year":"2004","journal-title":"Brain Dev."},{"key":"10.1016\/j.clim.2022.109039_bb0160","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1212\/01.wnl.0000250354.81556.90","article-title":"GPi deep brain stimulation for Tourette syndrome improves tics and psychiatric comorbidities","volume":"68","author":"Shahed","year":"2007","journal-title":"Neurology."},{"key":"10.1016\/j.clim.2022.109039_bb0165","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.autneu.2008.11.001","article-title":"Immunotherapy for autoimmune autonomic ganglionopathy","volume":"146","author":"Iodice","year":"2009","journal-title":"Auton. Neurosci. Basic Clin."},{"key":"10.1016\/j.clim.2022.109039_bb0170","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.revmed.2010.01.008","article-title":"Ganglionopathie autonomique auto-immune: une s\u00e9rie de six observations et revue de la litt\u00e9rature","volume":"31","author":"Parize","year":"2010","journal-title":"Rev. Med. Interne"},{"key":"10.1016\/j.clim.2022.109039_bb0175","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jneuroim.2018.03.018","article-title":"Seronegative and seropositive autoimmune autonomic ganglionopathy (AAG): Same clinical picture, same response to immunotherapy","volume":"319","author":"Tijero","year":"2018","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.clim.2022.109039_bb0180","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s10286-017-0493-8","article-title":"Seronegative autoimmune autonomic neuropathy: a distinct clinical entity","volume":"28","author":"Golden","year":"2018","journal-title":"Clin. Auton. Res."},{"key":"10.1016\/j.clim.2022.109039_bb0185","series-title":"Case of Autoimmune Autonomic Ganglionopathy Manifesting Anhidrosis","first-page":"1160","author":"Yoshifuku","year":"2017"},{"key":"10.1016\/j.clim.2022.109039_bb0190","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1007\/s00415-006-0378-6","article-title":"Immunoglobulin-responsive dysautonomia in Sj\u00f6gren\u2019s syndrome [5]","volume":"254","author":"Rajabally","year":"2007","journal-title":"J. Neurol."},{"key":"10.1016\/j.clim.2022.109039_bb0195","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1097\/MJT.0000000000000583","article-title":"Immunoresponsive autonomic neuropathy in Sj\u00f6gren syndrome - case series and literature review","volume":"26","author":"Goodman","year":"2019","journal-title":"Am. J. Ther."},{"key":"10.1016\/j.clim.2022.109039_bb0200","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.jocn.2013.02.016","article-title":"Dramatic efficacy of intravenous immunoglobulins in dysautonomic neurosarcoidosis","volume":"20","author":"Grignano","year":"2013","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.clim.2022.109039_bb0205","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.rmed.2010.09.015","article-title":"Efficacy of intravenous immunoglobulin for small fiber neuropathy associated with sarcoidosis","volume":"105","author":"Parambil","year":"2011","journal-title":"Respir. Med."},{"key":"10.1016\/j.clim.2022.109039_bb0210","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.rmed.2017.03.011","article-title":"Sarcoidosis-associated small fiber neuropathy in a large cohort: clinical aspects and response to IVIG and anti-TNF alpha treatment","volume":"126","author":"Tavee","year":"2017","journal-title":"Respir. Med."},{"key":"10.1016\/j.clim.2022.109039_bb0215","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1007\/s12026-016-8889-4","article-title":"Autonomic neuropathy\u2014in its many guises\u2014as the initial manifestation of the antiphospholipid syndrome","volume":"65","author":"Schofield","year":"2017","journal-title":"Immunol. Res."},{"key":"10.1016\/j.clim.2022.109039_bb0220","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1111\/j.1468-1331.2008.02305.x","article-title":"Effect of intravenous immunoglobulin on cerebellar ataxia and neuropathic pain associated with celiac disease","volume":"15","author":"Souayah","year":"2008","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.clim.2022.109039_bb0225","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s10072-011-0506-7","article-title":"Downbeat nystagmus, ataxia and spastic tetraparesis due to coeliac disease","volume":"32","author":"Habek","year":"2011","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.clim.2022.109039_bb0230","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJM199203053261001","article-title":"Weiss, The New England Journal of Medicine Downloaded from www.nejm.org at UNIVERSITY OF MICHIGAN on December 9, 2010. For personal use only. No other uses without permission. Copyright \u00a9 1992 Massachusetts Medical Society. All rights reserved","volume":"326","author":"Selby","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2022.109039_bb0235","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1212\/WNL.46.1.100","article-title":"Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barr\u00e9 syndrome","volume":"46","author":"Bril","year":"1996","journal-title":"Neurology."},{"key":"10.1016\/j.clim.2022.109039_bb0240","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1136\/jnnp.71.2.235","article-title":"Intravenous immune globulins in patients with Guillain-Barr\u00e9 syndrome and contraindications to plasma exchange: 3 days versus 6 days","volume":"71","author":"Raphael","year":"2001","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.clim.2022.109039_bb0245","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0140-6736(03)15324-X","article-title":"Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome: randomised trial","volume":"363","author":"Van Koningsveld","year":"2004","journal-title":"Lancet."},{"key":"10.1016\/j.clim.2022.109039_bb0250","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1542\/peds.2004-1324","article-title":"Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barr\u00e9 syndrome: a randomized trial","volume":"116","author":"Korinthenberg","year":"2005","journal-title":"Pediatrics."},{"key":"10.1016\/j.clim.2022.109039_bb0255","doi-asserted-by":"crossref","first-page":"R164","DOI":"10.1186\/cc10305","article-title":"Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain Barr\u00e9 syndrome: a randomized study","volume":"15","author":"El-Bayoumi","year":"2011","journal-title":"Crit. Care"},{"key":"10.1016\/j.clim.2022.109039_bb0260","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/tme.12169","article-title":"Comparison on therapeutic effect of plasma exchange and intravenous immunoglobulin for Guillian-Barre syndrome","volume":"25","author":"Ye","year":"2015","journal-title":"Transfus. Med."},{"key":"10.1016\/j.clim.2022.109039_bb0265","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/jca.21646","article-title":"Cost-minimization analysis in the Indian subcontinent for treating Guillain Barre Syndrome patients with therapeutic plasma exchange as compared to intravenous immunoglobulin","volume":"33","author":"Maheshwari","year":"2018","journal-title":"J. Clin. Apher."},{"key":"10.1016\/j.clim.2022.109039_bb0270","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/brain\/119.4.1067","article-title":"Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study","volume":"119","author":"Hahn","year":"1996","journal-title":"Brain."},{"key":"10.1016\/j.clim.2022.109039_bb0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/NXI.0000000000000586","article-title":"Randomized, controlled crossover study of IVIg for demyelinating polyneuropathy and diabetes","volume":"6","author":"Breiner","year":"2019","journal-title":"Neurol. Neuroimmunol. NeuroInflammation."},{"key":"10.1016\/j.clim.2022.109039_bb0280","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/jns.12302","article-title":"Efficacy and safety of IVIG in CIDP: combined data of the PRIMA and PATH studies","volume":"24","author":"Merkies","year":"2019","journal-title":"J. Peripher. Nerv. Syst."},{"key":"10.1016\/j.clim.2022.109039_bb0285","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/cen3.12137","article-title":"Combined immunomodulatory therapies resulted in stepwise recovery in autoimmune autonomic ganglionopathy","volume":"6","author":"Nishihara","year":"2015","journal-title":"Clin. Exp. Neuroimmunol."},{"key":"10.1016\/j.clim.2022.109039_bb0290","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jneuroim.2018.03.018","article-title":"Seronegative and seropositive autoimmune autonomic ganglionopathy (AAG): same clinical picture, same response to immunotherapy","volume":"319","author":"Tijero","year":"2018","journal-title":"J. Neuroimmunol."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661622001206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661622001206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:06:05Z","timestamp":1761494765000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661622001206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":58,"alternative-id":["S1521661622001206"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2022.109039","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravenouse immunoglobuline in dysautonomia","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2022.109039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109039"}}